Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Elisabet AliagasAnia AlayMaria Martínez-IniestaMiguel Hernández-MadrigalDavid CorderoMireia GausachsEva ProsMaria SaigíSara BusaccaAnnabel J SharkleyAlan DawsonRamón PalmeroJosé C RuffinelliSusana PadronesSamantha AsoIgnacio EscobarRicard RamosRoger LlatjósAugust Vidal BelEduard DorcaMar VarelaMontse Sánchez-CéspedesDean FennellCristina Muñoz-PinedoAlberto VillanuevaXavier SoléErnest NadalPublished in: British journal of cancer (2021)
Treatment of MPM with CDK4/6 inhibitors decreased cell proliferation, mainly by promoting cell cycle arrest at G1 and by induction of cell senescence. Our preclinical studies provide evidence for evaluating CDK4/6 inhibitors in the clinic for the treatment of MPM.